date:May 21, 2012
e gaining access to ONCs Powder-loc omega-3 manufacturing technologies that can be transferred to other parts of its portfolio.
It is DSMs fifth acquisition since it announced in 2010 its shift from being a fine chemicals player with a line in nutrients to a more focused life sciences company, and it has made no secret of its ongoing ambition (and funds) to buy in more nutritional firms and processes.
Bolt-on growth
One analyst told Reuters the move was in line with DSM acquisition strategies